Phase 4 Heart Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have had a heart attack (specifically a type called STEMI) and are planned to have a procedure to open a blocked artery (called PCI or stent placement)
• People whose heart attack is confirmed by at least 20 minutes of chest discomfort at rest, along with specific changes seen on a heart tracing (ECG) — either elevation in certain areas of the ECG, or a new abnormal electrical pattern in the heart
• People who, at a follow-up visit between 30 and 45 days after the procedure, have been consistently taking their two blood-thinning medications as prescribed with no changes to the regimen
• People who have not experienced a serious health event (such as another heart attack, unplanned repeat procedure, stroke, or major bleeding) between their procedure and the 30–45 day follow-up visit
• People whose stent procedure was considered technically successful, with the treated artery showing less than 30% blockage remaining
• People who have had all significant blockages treated — either during the main procedure or in follow-up procedures within 15 days

Who may not be able to join:

• People who are already taking blood-thinning tablets (oral anticoagulants)
• People who cannot safely take certain blood-thinning medications due to allergies or medical history — including people who have had a stroke or mini-stroke in the last 12 months, have active bleeding problems, severe liver disease, certain types of asthma triggered by pain-relief medicines, stomach ulcers or perforations, severe heart failure, or who take a high-dose chemotherapy drug called methotrexate
• People taking certain medications that interact with the trial drug (confirm with trial site for the full list, which includes some antifungal, antibiotic, HIV, and seizure medications, as well as large amounts of grapefruit juice)
• People with a very low platelet count (below 100,000 per microlitre) at the time of screening
• People with low haemoglobin (below 10 g/dL, a measure of anaemia) at the time of screening
• People with other serious illnesses where life expectancy is estimated to be less than one year
• People who are pregnant, have given birth in the last 90 days, or are currently breastfeeding
• People having the stent procedure specifically because a previous stent has clotted, or who have a confirmed history of stent clotting
• People who need major surgery that cannot be delayed while on dual blood-thinning medication after the procedure
• People who are in cardiogenic shock (when the heart is too weak to pump enough blood to the body)
• People who had a cardiac arrest outside of hospital, unless they recovered quickly with a normal heart rhythm restored promptly
• People with severely reduced kidney function (confirm specific measurement threshold with trial site)
• People who have taken part in another clinical trial involving a device or drug in the past 12 months, or who received an experimental drug in the 30 days before screening (or longer, depending on the drug)
• People who have not given informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.